X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Lupin Ltd with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs ACTAVIS (US) - Comparison Results

LUPIN    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 LUPIN   ACTAVIS
EQUITY SHARE DATA
    LUPIN
Mar-18
ACTAVIS
Dec-18
LUPIN/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs1,46513,413-   
Low Rs7278,998-   
Sales per share (Unadj.) Rs349.63,290.3-  
Earnings per share (Unadj.) Rs5.6-1,059.8-  
Cash flow per share (Unadj.) Rs29.6346.7-  
Dividends per share (Unadj.) Rs5.000-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs300.313,571.0-  
Shares outstanding (eoy) m452.08332.60-   
Bonus/Rights/Conversions ESOPS--  
Price / Sales ratio x3.13.4 92.1%   
Avg P/E ratio x197.2-10.6 -1,865.2%  
P/CF ratio (eoy) x37.132.3 114.7%  
Price / Book Value ratio x3.60.8 442.0%  
Dividend payout %90.00-   
Avg Mkt Cap Rs m495,5023,726,975 13.3%   
No. of employees `00017.016.9 100.8%   
Total wages/salary Rs m28,6470-   
Avg. sales/employee Rs Th9,273.664,754.7 14.3%   
Avg. wages/employee Rs Th1,681.00-   
Avg. net profit/employee Rs Th147.4-20,857.5 -0.7%   
INCOME DATA
Net Sales Rs m158,0421,094,355 14.4%  
Other income Rs m1,50420,928 7.2%   
Total revenues Rs m159,5451,115,283 14.3%   
Gross profit Rs m31,47528,678 109.8%  
Depreciation Rs m10,859467,813 2.3%   
Interest Rs m2,04463,151 3.2%   
Profit before tax Rs m20,076-481,358 -4.2%   
Minority Interest Rs m-710-   
Prior Period Items Rs m350-   
Extraordinary Inc (Exp) Rs m-14,644122,766 -11.9%   
Tax Rs m2,885-6,100 -47.3%   
Profit after tax Rs m2,513-352,492 -0.7%  
Gross profit margin %19.92.6 760.0%  
Effective tax rate %14.41.3 1,133.8%   
Net profit margin %1.6-32.2 -4.9%  
BALANCE SHEET DATA
Current assets Rs m122,095448,847 27.2%   
Current liabilities Rs m50,956397,065 12.8%   
Net working cap to sales %45.04.7 951.3%  
Current ratio x2.41.1 212.0%  
Inventory Days Days8520 431.9%  
Debtors Days Days12066 180.8%  
Net fixed assets Rs m129,876123,875 104.8%   
Share capital Rs m9040-   
"Free" reserves Rs m134,8660-   
Net worth Rs m135,7714,513,702 3.0%   
Long term debt Rs m64,2451,589,438 4.0%   
Total assets Rs m263,0547,055,944 3.7%  
Interest coverage x10.8-6.6 -163.5%   
Debt to equity ratio x0.50.4 134.4%  
Sales to assets ratio x0.60.2 387.4%   
Return on assets %1.7-4.1 -42.2%  
Return on equity %1.9-7.8 -23.7%  
Return on capital %3.7-4.8 -76.8%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m33,8070-   
CASH FLOW
From Operations Rs m17,512390,972 4.5%  
From Investments Rs m-14,073214,788 -6.6%  
From Financial Activity Rs m-14,921-671,025 2.2%  
Net Cashflow Rs m-11,482-64,939 17.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 69.32 Rs / USD

Compare LUPIN With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare LUPIN With: FRESENIUS KABI ONCO.  DR. DATSONS LABS  TORRENT PHARMA  AUROBINDO PHARMA  FULFORD INDIA  



Today's Market

Sensex Opens Marginally Higher; Capital Goods & Power Stocks Lead(09:30 am)

Asian share markets slipped on Wednesday and the dollar pulled back from three-month lows after Federal Reserve officials tempered expectations in the markets for aggressive monetary easing.

Related Views On News

LUPIN Announces Quarterly Results (4QFY19); Net Profit Down 1.5% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, LUPIN has posted a net profit of Rs 3 bn (down 1.5% YoY). Sales on the other hand came in at Rs 44 bn (up 77.8% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN LTD Announces Quarterly Results (3QFY19); Net Profit Down 149.7% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, LUPIN LTD has posted a net profit of Rs 2 bn (down 149.7% YoY). Sales on the other hand came in at Rs 45 bn (up 78.0% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

LUPIN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of LUPIN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of LUPIN LTD. Also includes updates on the valuation of LUPIN LTD.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

Why I Believe Smallcaps Will Catch up to the Sensex(Profit Hunter)

Jun 14, 2019

Smallcaps have gone nowhere even as the Sensex makes new all-time highs. Find out why Richa believes this a good opportunity to invest in smallcaps.

Why Super Investor Kenneth Andrade is Bullish on Agri Stocks...and So Are We(The 5 Minute Wrapup)

Jun 21, 2019

Andrade gives his take on agriculture, an industry from which we have already recommended two stocks.

This Little-Known Opportunity Promises Both Health and Wealth for Your Grandchildren(Profit Hunter)

Jun 20, 2019

The next big opportunity that has the potential to make you both rich and healthy.

My Upcoming Stock Recommendation, Backed by Aberdeen Standard Investments, Scores 9.1/10(The 5 Minute Wrapup)

Jun 19, 2019

This month's Smart Money Secrets recommendation is from global super investor - Aberdeen Standard Investments.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


Jun 26, 2019 10:15 AM

TRACK LUPIN

LUPIN - PANACEA BIOTECH COMPARISON

COMPARE LUPIN WITH

MARKET STATS